Table 1 Baseline characteristics of study population based on the absence or presence of NOAF
|  | SR (n = 569) | NOAF (n = 47) | P |
|---|---|---|---|
Age (years) | 63 (52–72) | 71 (66–77) | < 0.001 |
Male, n (%) | 462 (81.2) | 33 (70.2) | 0.069 |
BMI (kg/m2) | 24.8 (23.7–26.3) | 25.4 (24.7–27.1) | 0.038 |
Hypertension, n (%) | 278 (48.9) | 29 (61.7) | 0.091 |
Diabetes mellitus, n (%) | 100 (17.6) | 16 (34.0) | 0.006 |
Smoking, n (%) | 305 (53.6) | 21 (44.7) | 0.239 |
Alcohol consumption, n (%) | 165 (29.0) | 16 (34.0) | 0.573 |
Killip class ≥ 2, n (%) | 95 (16.7) | 23 (48.9) | < 0.001 |
White blood cell (109/l) | 10.80 (8.80–12.85) | 13.30 (10.50–16.10) | < 0.001 |
Hemoglobin (g/l) | 143.0 (129.0–155.0) | 133.0 (122.0–142.0) | 0.003 |
Lymphocyte (109/l) | 1.2 (0.9–1.7) | 0.8 (0.3–1.2) | < 0.001 |
Neutrophil (109/l) | 8.70 (6.70–10.80) | 11.20 (8.30–13.70) | < 0.001 |
Monocyte (109/l) | 0.40 (0.30–0.60) | 0.70 (0.40–1.00) | < 0.001 |
Platelet (109/l) | 178.00(142.50–222.50) | 153.00(122.00–196.00) | 0.019 |
NLR | 7.58 (4.53–11.41) | 14.38 (7.56–38.00) | < 0.001 |
MLR | 0.33 (0.24–0.49) | 0.78 (0.50–2.75) | < 0.001 |
SIRI | 2.80 (1.69–4.80) | 7.38 (5.11–24.00) | < 0.001 |
Glucose (mmol/l) | 5.57 (4.79–6.87) | 7.38 (5.57–9.62) | < 0.001 |
Total cholesterol (mmol/l) | 4.13 (3.55–4.89) | 3.89 (3.20–4.53) | 0.068 |
Triglyceride (mmol/l) | 1.46 (1.04–2.08) | 1.63 (1.22–2.08) | 0.282 |
HDL-c (mmol/l) | 1.16 (1.02–1.32) | 1.31 (1.15–1.44) | 0.002 |
LDL-c (mmol/l) | 2.40 (2.01–2.96) | 2.06 (1.70–2.63) | 0.005 |
eGFR (ml/min*1.73m2) | 121.78 (97.69–149.71) | 94.82 (83.22–130.24) | 0.001 |
Peak CK (103U/L) | 1.59 (0.85–2.76) | 1.84 (0.99–3.46) | 0.244 |
Albumin (g/l) | 36.48 ± 3.69 | 33.86 ± 3.15 | < 0.001 |
Culprit vessels, n (%) | |||
 LAD | 310 (54.5) | 24 (51.1) | 0.764 |
 LCX | 48 (8.4) | 2 (4.3) | 0.465 |
 RCA | 211 (37.1) | 21 (44.7) | 0.301 |
TIMI 3 flow pre-PCI, n (%) | 117 (20.6) | 6 (12.8) | 0.199 |
Stent-length (mm) | 29 (21–33) | 29 (23–36) | 0.055 |
SYNTAX score | 19.0 (13.0–23.5) | 21.0 (15.0–25.5) | 0.050 |
Residual SYNTAX score | 4.0 (0–9.0) | 5.0 (2.0–12.0) | 0.070 |
LA (mm) | 36 (34–40) | 40 (38–42) | < 0.001 |
LVEF (%) | 52 (48–56) | 48 (42–55) | 0.002 |
Medications in-hospital | |||
 ACEI/ARB, n (%) | 276 (48.7) | 24 (52.2) | 0.762 |
 Beta-blocker, n (%) | 372 (65.6) | 20 (43.5) | 0.003 |
 MRA, n (%) | 98 (17.3) | 19 (41.3) | < 0.001 |
 Statin, n (%) | 515 (90.5) | 42 (89.4) | 0.797 |
In-hospital outcomes | |||
 Cerebrovascular events, n (%) | 5 (0.9) | 2 (4.3) | 0.036 |
 Pulmonary edema, n (%) | 55 (9.7) | 20 (42.6) | < 0.001 |
 Cardiogenic shock, n (%) | 62 (10.9) | 15 (31.9) | < 0.001 |
 Mortality, n (%) | 17 (3.0) | 6 (12.8) | 0.001 |
 VT, n (%) | 16 (2.9) | 6 (13.0) | < 0.001 |